In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Several years after the COVID-19 vaccine's rollout, the only federal program that provides compensation for COVID vaccine ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

US Health and Human Services Secretary Robert F. Kennedy Jr. said Monday that he is working with the Justice Department to ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The Biden administration is supporting collaboration between Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) to produce more COVID-19 vaccine doses through the Defense Production Act.

Pharmalittle: We’re reading about Merck eyeing a biotech, a Moderna Covid vaccine trial, and more FDA Commissioner Marty Makary committed to reviewing the abortion drug mifepristone Alex Hogan/STAT ...